SEC Tracker
Get the app

Biovie BIVI

Biovie FY 2024: net loss $32.1M; diluted EPS −$7.30

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Biovie reported for the year ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$32.1MAgainst −$50.3M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$7.30Against −$1.55 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$23.8M+23% from $19.5M in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$27.9MAgainst −$40.3M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Biovie files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. GT Biopharma GTBP public float $9M, Jun 30, 2025
  2. Talphera TLPH public float $8M, Jun 30, 2025
  3. Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
  4. TherapeuticsMD TXMD public float $9M, Jun 30, 2025
  5. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025